January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
2 citations
,
January 2012 in “PubMed” Mycophenolate mofetil is effective for treating severe lupus nephritis in children.
21 citations
,
May 2018 in “Journal of Cosmetic Dermatology” Costunolide helps human hair cells grow and can stimulate hair growth in mice.
11 citations
,
January 1984 in “Veterinary Pathology” 42 citations
,
September 2012 in “PLoS ONE” Bezafibrate treatment improved skin and spleen health in aging mice but didn't extend lifespan.
16 citations
,
August 2003 in “Journal of The American Academy of Dermatology” Nitrogen mustard was not very effective for hair regrowth in alopecia areata and has potential skin cancer risk.
55 citations
,
June 1987 in “PubMed” Cyclosporin A significantly increases hair growth in certain areas of mice.
27 citations
,
December 2014 in “Current problems in dermatology” Photodynamic therapy is the preferred treatment for skin precancer due to its effectiveness and safety.
2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
5 citations
,
January 2016 in “Indian dermatology online journal” A 25-year-old man with multiple skin tumors was successfully treated with acitretin and methotrexate.
39 citations
,
August 2022 in “Pharmaceutics” Combining letrozole and quercetin in spanlastics may improve breast cancer treatment.
5 citations
,
August 2024 in “Frontiers in Immunology” Upadacitinib effectively treats psoriasiform eczema and some related conditions.
10 citations
,
January 1994 in “Advances in pharmacology” New drugs targeting DNA enzymes show promise for cancer treatment but have side effects like immune system suppression and hair loss.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Linoleic acid and magnesium are key in alopecia areata progression, and tofacitinib can help by affecting their pathway.
2 citations
,
October 2022 in “British journal of haematology” A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.
March 2026 in “Korean Journal of Clinical Pharmacy” In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.
1 citations
,
March 2023 in “Anais Brasileiros de Dermatologia”
17 citations
,
April 2004 in “Acta Clinica Belgica” UV light makes skin signs of lack of carotene and vitamin A more visible.
March 2014 in “Journal of The American Academy of Dermatology” Azathioprine treatment led to rapid hair regrowth in a woman with alopecia universalis.
The treatment was ineffective in humans.
3 citations
,
May 2021 in “Genetics and Biodiversity Journal” Citrullus colocynthis fruit extract has strong antioxidant and cancer-fighting potential.
Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.
3 citations
,
August 2019 in “Journal of Cancer Research and Therapeutics” Cetuximab can cause unusual hair growth and hair loss.
7 citations
,
August 2019 in “Bioorganic & medicinal chemistry” Analog 23 is a promising compound for prostate cancer treatment.
October 2023 in “Regular and Young Investigator Award Abstracts” Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.
20 citations
,
June 2019 in “Archives of dermatological research” Combining DPCP and anthralin helps regrow hair in some alopecia areata patients.
May 2025 in “The Journal of Rheumatology” Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.
7 citations
,
August 2024 in “Clinical and Experimental Dermatology” Upadacitinib is effective and safe for treating severe alopecia areata in teens.
3 citations
,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.